Table 1.
Prevalence of RAS mutations in patients with metastatic colorectal carcinoma
| Study | Detection method | RAS mutation prevalence | ||||||
|---|---|---|---|---|---|---|---|---|
| KRAS | NRAS | Total | ||||||
| Exon 2 | Exon 3 | Exon 4 | Exon 2 | Exon 3 | Exon 4 | |||
| PRIME [14] | TheraScreen | 40 % | 4 %a | 6 % | 3 % | 4 %a | 0 % | 52 %a |
| 20050408 [19] | DxS/Qiagen/NGS/Sanger | 42 % | 2 %a | NS | 5 %a | NS | NS | |
| 20050408 (updated) [26] | NGS/Sanger + WAVE/SURVEYOR® | 43 % | 5 %a | 5 % | 4 % | 3 %a | 1 % | NS |
| 20050181 [25] | DxS/Qiagen/NGS/Sanger | 45 % | 4 % | 8 % | 2 % | 6 % | 0 % | 58 % |
| PICCOLO [27] | Pyrosequencing | NAb | NAb | 4 %c | 6 %a | NS | NS | |
| PEAK [18] | Therascreen + WAVE/SURVEYOR® | NAd | 4 % | 7 % | 5 % | 6 % | 0 % | NS |
| CRYSTAL [10] | LightMix | 36 % | NS | NS | NS | NS | NS | NS |
| CRYSTAL (updated) [28] | BEAMing | 37 % | 3 % | 5 % | 4 % | 3 % | 2 % | 43 % |
| COIN [29] | Pyrosequencing | 43 %a | NS | 4 %a,e | NS | NS | ||
| FIRE-3 [30] | Pyrosequencing | NAd | 4 % | 5 % | 4 % | 2 % | 0 % | NS |
| OPUS [31] | BEAMing | NAd | 6 % | 9 % | 7 % | 5 % | 1 % | NS |
BEAM beads, emulsions, amplification, and magnetics, NGS next-generation sequencing, NS not specified, PCR polymerase chain reaction
aNot including codon 59
bStudy population limited to patients with KRAS (exon 2 and exon 3 codon 61) wild-type tumors
cNot including codon 117
dStudy population limited to patients with KRAS (exon 2) wild-type tumors
eNot including codon 13